Gu Yaowen, Zheng Si, Yin Qijin, Jiang Rui, Li Jiao
Institute of Medical Information (IMI), Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, 100020, China.
Institute of Medical Information (IMI), Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, 100020, China; Institute for Artificial Intelligence, Department of Computer Science and Technology, BNRist, Tsinghua University, Beijing, 100084, China.
Comput Biol Med. 2022 Nov;150:106127. doi: 10.1016/j.compbiomed.2022.106127. Epub 2022 Sep 22.
Computational drug repositioning is an effective way to find new indications for existing drugs, thus can accelerate drug development and reduce experimental costs. Recently, various deep learning-based repurposing methods have been established to identify the potential drug-disease associations (DDA). However, effective utilization of the relations of biological entities to capture the biological interactions to enhance the drug-disease association prediction is still challenging. To resolve the above problem, we proposed a heterogeneous graph neural network called REDDA (Relations-Enhanced Drug-Disease Association prediction). Assembled with three attention mechanisms, REDDA can sequentially learn drug/disease representations by a general heterogeneous graph convolutional network-based node embedding block, a topological subnet embedding block, a graph attention block, and a layer attention block. Performance comparisons on our proposed benchmark dataset show that REDDA outperforms 8 advanced drug-disease association prediction methods, achieving relative improvements of 0.76% on the area under the receiver operating characteristic curve (AUC) score and 13.92% on the precision-recall curve (AUPR) score compared to the suboptimal method. On the other benchmark dataset, REDDA also obtains relative improvements of 2.48% on the AUC score and 4.93% on the AUPR score. Specifically, case studies also indicate that REDDA can give valid predictions for the discovery of -new indications for drugs and new therapies for diseases. The overall results provide an inspiring potential for REDDA in the in silico drug development. The proposed benchmark dataset and source code are available in https://github.com/gu-yaowen/REDDA.
计算药物重新定位是为现有药物寻找新适应症的有效方法,因此可以加速药物开发并降低实验成本。最近,已经建立了各种基于深度学习的重新定位方法来识别潜在的药物-疾病关联(DDA)。然而,有效利用生物实体之间的关系来捕捉生物相互作用以增强药物-疾病关联预测仍然具有挑战性。为了解决上述问题,我们提出了一种名为REDDA(关系增强药物-疾病关联预测)的异构图神经网络。REDDA由三种注意力机制组成,它可以通过基于通用异构图卷积网络的节点嵌入块、拓扑子网嵌入块、图注意力块和层注意力块依次学习药物/疾病表示。在我们提出的基准数据集上的性能比较表明,REDDA优于8种先进的药物-疾病关联预测方法,与次优方法相比,在受试者工作特征曲线(AUC)下面积得分上实现了0.76%的相对提升,在精确率-召回率曲线(AUPR)得分上实现了13.92%的相对提升。在另一个基准数据集上,REDDA在AUC得分上也获得了2.48%的相对提升,在AUPR得分上获得了4.93%的相对提升。具体而言,案例研究还表明,REDDA可以为药物新适应症的发现和疾病新疗法的发现给出有效的预测。总体结果为REDDA在计算机辅助药物开发中提供了鼓舞人心的潜力。所提出的基准数据集和源代码可在https://github.com/gu-yaowen/REDDA上获取。